National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
Division of Microbiology and Infectious Diseases.
J Infect Dis. 2018 Jul 2;218(3):347-354. doi: 10.1093/infdis/jiy103.
A priority for the National Institute of Allergy and Infectious Diseases is development of a universal influenza vaccine providing durable protection against multiple influenza strains. NIAID will use this strategic plan as a foundation for future investments in influenza research.
美国过敏和传染病研究所的一个优先事项是开发一种通用流感疫苗,为多种流感株提供持久保护。NIAID 将把这个战略计划作为未来流感研究投资的基础。